CEL-SCI Corporation news

   Watch this stock
Showing stories 61 - 70 of about 88   

Articles published

CVM 1.89 +0.09 (4.70%)
price chart
Rheumatoid Arthritis Vaccine Candidate Suppresses Disease Progression in Mice
“Current treatments for RA focus on the alleviation of symptoms and delaying disease progression,” Dr Zimmerman, senior vice president of research, Cellular Immunology at CEL-SCI Corporation, said in a press release. “Our vaccination approach attempts ...
The CEL-SCI (CVM) Getting Positive Press Coverage, Analysis Shows
About CEL-SCI CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system.
The CEL-SCI (CVM) Given Coverage Optimism Rating of 0.56
CEL-SCI has a 12-month low of $0.06 and a 12-month high of $0.55. The company's market capitalization is $19.88 million. CEL-SCI (NYSEMKT:CVM) last announced its quarterly earnings results on Wednesday, May 10th.
Smallpox Market Therapeutic Pipeline H2, Drug Profile, Market Scope, Regional ...
Smallpox Market H2, latest research provides in depth analysis of Key players with pipeline review and targeted therapeutics covering drugs profile of Smallpox industry.
T Cell Surface Glycoprotein CD4 Market Therapeutic Pipeline H2 Drugs ...
T Cell Surface Glycoprotein CD4 Market H2, latest research provides in depth analysis of Key players with pipeline review and targeted therapeutics covering drugs profile of T Cell Surface Glycoprotein CD4 industry.
Kistler-Tiffany Companies Lowered Altria Group (MO) Position By $384874; Cel ...
With 162,300 avg volume, 4 days are for Cel Sci Corporation (NYSEAMERICAN:CVM)'s short sellers to cover CVM's short positions.
Shell Asset Management Co Has Cut Dexcom (DXCM) Position By $1.32 Million; Cel ...
Cel Sci Corporation (NYSEAMERICAN:CVM) had a decrease of 12.78% in short interest. CVM's SI was 583,300 shares in December as released by FINRA.
Future of the Global T Cell Surface Glycoprotein CD4 Market – Growth, Latest ...
The statistics in the research focuses on the technological advancement, available capaciies,CAPEX cycle and the changing structure of the Global T Cell Surface Glycoprotein CD4 market.
Rising Prevalence of Infectious Diseases and Favorable Government Initiatives ...
This report also provides the existing competitive scenario of some of the key players of the global therapeutic vaccines market which includes company profiling of Cytos Biotechnology, Agenus Inc., Bavarian Nordic, Celldex Therapeutics, Affiris AG ...
Global T Cell Surface Glycoprotein CD4 Market 2017- Sanofi, Biotest AG ...
A market study based on the “Global T Cell Surface Glycoprotein CD4 Market” across the globe, recently added to the repository of Market Research, is titled 'Global T Cell Surface Glycoprotein CD4 Market 2017'.